- Home
- SXC vs KURA Comparison
SXC vs KURA Comparison
Compare SXC & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SXC | KURA |
|---|---|---|
| Founded | 1960 | 2014 |
| Country | United States | United States |
| Employees | 2477 | 260 |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 961.6M | 912.7M |
| IPO Year | 2011 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SXC | KURA |
|---|---|---|
| Price | $11.24 | $10.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | $10.50 | ★ $31.85 |
| AVG Volume (30 Days) | 976.1K | ★ 1.6M |
| Earning Date | 10-27-2026 | 11-10-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,600,300,000.00 | $67,482,000.00 |
| Revenue This Year | $0.68 | $43.07 |
| Revenue Next Year | N/A | $117.06 |
| P/E Ratio | $30.71 | ★ N/A |
| Revenue Growth | 10.30 | ★ 25.24 |
| 52 Week Low | $5.52 | $7.36 |
| 52 Week High | $11.12 | $13.90 |
Technical Indicators
Market Signals| Indicator | SXC | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 67.89 | 48.27 |
| Support Level | $9.14 | $8.65 |
| Resistance Level | N/A | $11.32 |
| Average True Range (ATR) | 0.38 | 0.53 |
| MACD | 0.11 | 0.13 |
| Stochastic Oscillator | 95.31 | 62.98 |
Price Performance
Historical ComparisonAbout SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.